Doximity, INC

Doximity announces the formal resignation of CFO Anna Bryson and reaffirms its existing financial guidance.

Doximity, Inc. announced its fiscal Q3 2026 financial results with 10% revenue growth, strong user engagement, a new $500 million stock repurchase program, and a temporary medical leave for its CFO.

Doximity, Inc. announced a $31 million settlement, fully covered by insurance, to resolve a securities litigation lawsuit, pending court approval.

Doximity reports strong fiscal Q2 2026 results with 23% revenue growth and significant increases in profitability and cash flow, driven by expanding AI tool adoption.

Doximity, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all three proposals, including director elections and auditor ratification, were approved.

Doximity, Inc. announced a change in its General Counsel, Corporate Secretary, and Chief Compliance Officer roles, effective August 29, 2025.

Doximity reported a 10% revenue increase for Q3 FY2026, reaching $185.1 million, while net income decreased to $61.6 million.

Doximity, Inc. reports strong second-quarter fiscal 2026 results with significant revenue and net income growth, driven by subscription expansion and a strategic AI acquisition.

Doximity, the leading digital platform for U.S. medical professionals, reported strong first-quarter results with a 15% revenue increase and a 29% rise in net income, alongside a strategic acquisition and ongoing share repurchases.

Doximity's Q3 2025 results show a 25% increase in revenue compared to the same period last year, driven by subscription growth.

Doximity's Q2 2025 results show a 20% year-over-year revenue increase, driven by growth in subscription services and customer expansion.

Doximity, a leading digital platform for U.S. medical professionals, announced a 17% year-over-year revenue increase for the first quarter of fiscal year 2025, alongside a rise in net income, while also facing ongoing legal proceedings.

Doximity, Inc. announced its annual report for the fiscal year ended March 31, 2026, highlighting a 13% increase in revenue to $644.9 million and a net income of $196.1 million.

Doximity's fiscal year 2025 shows revenue growth and profitability, fueled by its expanding network of medical professionals and increasing customer subscriptions.

Doximity, Inc. released its annual report for fiscal year 2024, highlighting a 13% revenue increase and outlining strategies for future growth.

Jeffrey Tangney, Chief Executive Officer, a Director and 10% owner of Doximity, Inc., received 2,480,000 shares of common stock on July 22, 2026.

Steven L Zatz, President of Doximity, Inc., received 150,000 shares of common stock on July 22, 2026.

Siddharth Sitaram, Chief Accounting Officer of Doximity, Inc., sold 1,732 shares of common stock on July 15, 2026 for $22.02 per share.

Regina M. Benjamin, a Director of Doximity, Inc., received 9,750 shares of common stock on November 15, 2025.

Regina M. Benjamin, a Director of Doximity, Inc., received 21,314 shares of common stock on July 13, 2026.

Doximity Inc. President Steven L. Zatz reported transactions involving restricted stock units, with vesting scheduled over the next year.

Doximity, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for August 27, 2026, detailing proposals for director elections, auditor ratification, and executive compensation.

Doximity, Inc. has filed a Definitive Proxy Statement (Schedule 14A) with the U.S. Securities and Exchange Commission.

Doximity, Inc. announced its fiscal year 2025 results, revealing revenue and adjusted EBITDA exceeding targets, while also detailing proposals for its upcoming Annual Meeting of Stockholders and disclosing ongoing securities and derivative lawsuits.

Doximity, Inc. has filed a definitive proxy statement with the SEC.

Doximity, Inc. announces its Annual Meeting of Stockholders for fiscal year 2024, to be held virtually on August 29, 2024, to elect directors, ratify the appointment of the independent auditor, and approve executive compensation.

Jeffrey Tangney and Claudia Schweikert report continued significant beneficial ownership and voting control in Doximity, Inc.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.07% beneficial ownership stake in Doximity Inc.

The Vanguard Group has reported 0% beneficial ownership in Doximity Inc. following an internal realignment that disaggregated its reporting of beneficial ownership.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 1.6% beneficial ownership in Doximity Inc.'s Class A Common Stock as of December 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 6.4% beneficial ownership in Doximity Inc.'s Class A Common Stock as of September 30, 2025.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 8.1% of Doximity Inc.'s Class A Common Stock, totaling 11,096,000.02 shares.